Joint Nordic prospective study on human herpesvirus 8 and multiple myeloma risk.
An association between human herpesvirus 8 (HHV8) and multiple myeloma (MM) has been reported, though most studies have not confirmed such association. To follow-up on a previous prospective seroepidemiological study, where HHV8 tended to associate with MM risk, we linked five large serum banks in the Nordic countries with the Nordic cancer registries and 329 prospectively occurring cases of MM were identified, together with 1631 control subjects matched by age and gender. The HHV8 seroprevalences among cases and controls were similar (12 and 15%, respectively) and HHV8 seropositivity did not associate with the risk of MM, neither when considering positivity for lytic antibodies (relative risk (RR) = 0.8, 95% confidence interval (CI) = 0.5-1.1) nor for latent antibodies (RR = 0.6, 95% CI = 0.1-2.7). Similar risks were seen when analysis was restricted to case-control sets with at least 2 years lag before diagnosis (RR = 0.8, 95% CI = 0.5-1.2 and RR = 0.9, 95% CI = 0.1-4.2). In conclusion, the data indicate that HHV8 infection is not associated with MM.
Tedeschi
R
R
Department of Microbiology-Immunology and Virology, Centro di Riferimento Oncologico, Aviano, Italy.
Luostarinen
T
T
De Paoli
P
P
Gislefoss
R E
RE
Tenkanen
L
L
Virtamo
J
J
Koskela
P
P
Hallmans
G
G
Lehtinen
M
M
Dillner
J
J
D000914:Antibodies, Viral / Q000097:blood; D016022:Case-Control Studies; D015331:Cohort Studies; D005260:Female; D005387:Finland; D019288:Herpesvirus 8, Human / Q000276:immunology / Q000302:isolation & purification*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D009101:Multiple Myeloma / Q000097:blood / Q000821:virology*; D009664:Norway; D012307:Risk Factors
D000914:Antibodies, Viral; D007074:Immunoglobulin G